| Year |
Citation |
Score |
| 1974 |
Jakes K, Zinder ND, Boon T. Purification and properties of colicin E3 immunity protein. The Journal of Biological Chemistry. 249: 438-44. PMID 4588566 |
0.425 |
|
| 1974 |
Boon T, Buckingham ME, Dexter DL, Jakob H, Jacob F. [Mouse teratocarcinoma: isolation and characterization of two muscle cell lines (author's transl)]. Annales De Microbiologie. 125: 13-28. PMID 4468749 |
0.33 |
|
| 1973 |
Jakob H, Boon T, Gaillard J, Nicolas J, Jacob F. [Teratocarcinoma of the mouse: isolation, culture and properties of pluripotential cells]. Annales De Microbiologie. 124: 269-82. PMID 4599372 |
0.344 |
|
| 1971 |
Boon T, Zinder ND. Genotypes produced by individual recombination events involving bacteriophage f1. Journal of Molecular Biology. 58: 133-51. PMID 5088923 DOI: 10.1016/0022-2836(71)90237-3 |
0.517 |
|
| 1970 |
Boon T, Zinder ND. Genetic recombination in bacteriophage f1: transfer of parental DNA to the recombinant. Virology. 41: 444-52. PMID 4912819 DOI: 10.1016/0042-6822(70)90165-0 |
0.517 |
|
| 1969 |
Boon T, Zinder ND. A mechanism for genetic recombination generating one parent and one recombinant. Proceedings of the National Academy of Sciences of the United States of America. 64: 573-7. PMID 5261034 DOI: 10.1073/Pnas.64.2.573 |
0.496 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 1992 |
Traversari C, van der Bruggen P, Van den Eynde B, Hainaut P, Lemoine C, Ohta N, Old L, Boon T. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics. 35: 145-52. PMID 1537606 DOI: 10.1007/BF00185107 |
0.228 |
|
| 1987 |
Wölfel T, Van Pel A, De Plaen E, Lurquin C, Maryanski JL, Boon T. Immunogenic (tum-) variants obtained by mutagenesis of mouse mastocytoma P815. VIII. Detection of stable transfectants expressing a tum- antigen with a cytolytic T cell stimulation assay. Immunogenetics. 26: 178-87. PMID 3114137 DOI: 10.1007/BF00365909 |
0.226 |
|
| 1988 |
De Plaen E, Lurquin C, Van Pel A, Mariamé B, Szikora JP, Wölfel T, Sibille C, Chomez P, Boon T. Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. Proceedings of the National Academy of Sciences of the United States of America. 85: 2274-8. PMID 3127830 DOI: 10.1073/pnas.85.7.2274 |
0.226 |
|
| 1981 |
Boon T, Van Snick J, Van Pel A, Uyttenhove C, Marchand M. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. The Journal of Experimental Medicine. 152: 1184-93. PMID 6776227 DOI: 10.1084/jem.152.5.1184 |
0.206 |
|
| 1999 |
Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. The Journal of Experimental Medicine. 189: 767-78. PMID 10049940 DOI: 10.1084/jem.189.5.767 |
0.197 |
|
| 1990 |
Degiovanni G, Hainaut P, Lahaye T, Weynants P, Boon T. Antigens recognized on a melanoma cell line by autologous cytolytic T lymphocytes are also expressed on freshly collected tumor cells. European Journal of Immunology. 20: 1865-8. PMID 2209693 DOI: 10.1002/eji.1830200835 |
0.197 |
|
| 1988 |
Degiovanni G, Lahaye T, Hérin M, Hainaut P, Boon T. Antigenic heterogeneity of a human melanoma tumor detected by autologous CTL clones. European Journal of Immunology. 18: 671-6. PMID 2967757 DOI: 10.1002/eji.1830180503 |
0.196 |
|
| 1994 |
van der Bruggen P, Szikora JP, Boël P, Wildmann C, Somville M, Sensi M, Boon T. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. European Journal of Immunology. 24: 2134-40. PMID 7522162 DOI: 10.1002/eji.1830240930 |
0.195 |
|
| 1978 |
Boon T, Van Pel A. Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. Proceedings of the National Academy of Sciences of the United States of America. 75: 1519-23. PMID 274738 DOI: 10.1073/pnas.75.3.1519 |
0.194 |
|
| 1989 |
Knuth A, Wölfel T, Klehmann E, Boon T, Meyer zum Büschenfelde KH. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proceedings of the National Academy of Sciences of the United States of America. 86: 2804-8. PMID 2784858 DOI: 10.1073/pnas.86.8.2804 |
0.193 |
|
| 1982 |
Maryanski JL, Van Snick J, Cerottini JC, Boon T. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. European Journal of Immunology. 12: 401-6. PMID 6178607 DOI: 10.1002/eji.1830120508 |
0.193 |
|
| 2000 |
Morel S, Lévy F, Burlet-Schiltz O, Brasseur F, Probst-Kepper M, Peitrequin AL, Monsarrat B, Van Velthoven R, Cerottini JC, Boon T, Gairin JE, Van den Eynde BJ. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity. 12: 107-17. PMID 10661410 DOI: 10.1016/S1074-7613(00)80163-6 |
0.192 |
|
| 1989 |
Van den Eynde B, Hainaut P, Hérin M, Knuth A, Lemoine C, Weynants P, van der Bruggen P, Fauchet R, Boon T. Presence on a human melanoma of multiple antigens recognized by autologous CTL. International Journal of Cancer. 44: 634-40. PMID 2529220 DOI: 10.1002/ijc.2910440413 |
0.192 |
|
| 1992 |
Chomez P, De Plaen E, Van Pel A, De Smet C, Szikora JP, Lurquin C, Lebacq-Verheyden AM, Boon T. Efficient expression of tum- antigen P91A by transfected subgenic fragments. Immunogenetics. 35: 241-52. PMID 1541484 DOI: 10.1007/BF00166829 |
0.192 |
|
| 1991 |
Van den Eynde B, Lethé B, Van Pel A, De Plaen E, Boon T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. The Journal of Experimental Medicine. 173: 1373-84. PMID 1903428 DOI: 10.1084/jem.173.6.1373 |
0.191 |
|
| 1996 |
Warnier G, Duffour MT, Uyttenhove C, Gajewski TF, Lurquin C, Haddada H, Perricaudet M, Boon T. Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. International Journal of Cancer. 67: 303-10. PMID 8760603 DOI: 10.1002/(SICI)1097-0215(19960717)67:2<303::AID-IJC24>3.0.CO;2-A |
0.191 |
|
| 1995 |
Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T, Coulie PG. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. European Journal of Immunology. 25: 340-7. PMID 7875194 DOI: 10.1002/eji.1830250206 |
0.19 |
|
| 1993 |
Brichard V, Van Pel A, Wölfel T, Wölfel C, De Plaen E, Lethé B, Coulie P, Boon T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. The Journal of Experimental Medicine. 178: 489-95. PMID 8340755 DOI: 10.1084/jem.178.2.489 |
0.188 |
|
| 1996 |
Viale O, van der Bruggen P, Meuer E, Kunzmann R, Kohler H, Mertelsmann R, Boon T, Fisch P. Recognition by human Vgamma9/Vdelta2 T cells of melanoma cells upon fusion with Daudi cells. Immunogenetics. 45: 27-34. PMID 8881034 DOI: 10.1007/s002510050163 |
0.188 |
|
| 1989 |
Lurquin C, Van Pel A, Mariamé B, De Plaen E, Szikora JP, Janssens C, Reddehase MJ, Lejeune J, Boon T. Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell. 58: 293-303. PMID 2568889 DOI: 10.1016/0092-8674(89)90844-1 |
0.187 |
|
| 1996 |
Zarour H, De Smet C, Lehmann F, Marchand M, Lethé B, Romero P, Boon T, Renauld JC. The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100. The Journal of Investigative Dermatology. 107: 63-7. PMID 8752841 DOI: 10.1111/1523-1747.ep12298177 |
0.186 |
|
| 1994 |
Coulie PG, Weynants P, Lehmann F, Herman J, Brichard V, Wölfel T, Van Pel A, De Plaen E, Brasseur F, Boon T. Genes coding for tumor antigens recognized by human cytolytic T lymphocytes. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 14: 104-9. PMID 8280701 DOI: 10.1097/00002371-199308000-00004 |
0.186 |
|
| 1992 |
Lethé B, van den Eynde B, van Pel A, Corradin G, Boon T. Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. European Journal of Immunology. 22: 2283-8. PMID 1381312 DOI: 10.1002/eji.1830220916 |
0.184 |
|
| 1996 |
Brichard VG, Herman J, Van Pel A, Wildmann C, Gaugler B, Wölfel T, Boon T, Lethé B. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. European Journal of Immunology. 26: 224-30. PMID 8566071 DOI: 10.1002/eji.1830260135 |
0.184 |
|
| 2001 |
Karanikas V, Colau D, Baurain JF, Chiari R, Thonnard J, Gutierrez-Roelens I, Goffinet C, Van Schaftingen E, Weynants P, Boon T, Coulie PG. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival Cancer Research. 61: 3718-3724. PMID 11325844 |
0.182 |
|
| 1993 |
Szikora JP, Van Pel A, Boon T. Tum- mutation P35B generates the MHC-binding site of a new antigenic peptide. Immunogenetics. 37: 135-8. PMID 8423052 DOI: 10.1007/BF00216837 |
0.18 |
|
| 1994 |
Chen YT, Stockert E, Chen Y, Garin-Chesa P, Rettig WJ, van der Bruggen P, Boon T, Old LJ. Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Proceedings of the National Academy of Sciences of the United States of America. 91: 1004-8. PMID 8302824 DOI: 10.1073/Pnas.91.3.1004 |
0.179 |
|
| 1997 |
De Plaen E, Lurquin C, Lethé B, van der Bruggen P, Brichard V, Renauld JC, Coulie P, Van Pel A, Boon T. Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes. Methods (San Diego, Calif.). 12: 125-42. PMID 9184377 DOI: 10.1006/meth.1997.0462 |
0.179 |
|
| 1987 |
Hérin M, Lemoine C, Weynants P, Vessière F, Van Pel A, Knuth A, Devos R, Boon T. Production of stable cytolytic T-cell clones directed against autologous human melanoma. International Journal of Cancer. 39: 390-6. PMID 3493226 DOI: 10.1002/ijc.2910390320 |
0.179 |
|
| 1993 |
Marchand M, Brasseur F, van der Bruggen P, Coulie P, Boon T. Perspectives for immunization of HLA-A1 patients carrying a malignant melanoma expressing gene MAGE-1. Dermatology (Basel, Switzerland). 186: 278-80. PMID 8513199 DOI: 10.1159/000247375 |
0.177 |
|
| 1997 |
Ikeda H, Lethé B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 6: 199-208. PMID 9047241 DOI: 10.1016/S1074-7613(00)80426-4 |
0.177 |
|
| 2000 |
Baurain JF, Colau D, van Baren N, Landry C, Martelange V, Vikkula M, Boon T, Coulie PG. High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene. Journal of Immunology (Baltimore, Md. : 1950). 164: 6057-66. PMID 10820291 DOI: 10.4049/jimmunol.164.11.6057 |
0.175 |
|
| 1977 |
Boon T, Kellermann O. Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proceedings of the National Academy of Sciences of the United States of America. 74: 272-5. PMID 264681 DOI: 10.1073/pnas.74.1.272 |
0.175 |
|
| 1981 |
Uyttenhove C, Van Snick J, Boon T. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice. The Journal of Experimental Medicine. 152: 1175-83. PMID 6776226 DOI: 10.1084/jem.152.5.1175 |
0.173 |
|
| 2005 |
Ottaviani S, Zhang Y, Boon T, van der Bruggen P. A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells. Cancer Immunology, Immunotherapy : Cii. 54: 1214-20. PMID 16025263 DOI: 10.1007/S00262-005-0705-2 |
0.172 |
|
| 2005 |
van Baren N, Bonnet MC, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, Liénard D, Speiser D, Marchand M, Brichard VG, Escudier B, Négrier S, Dietrich PY, Maraninchi D, Osanto S, ... ... Boon T, et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 9008-21. PMID 16061912 DOI: 10.1200/JCO.2005.08.375 |
0.172 |
|
| 1999 |
Rimoldi D, Salvi S, Reed D, Coulie P, Jongeneel VC, De Plaen E, Brasseur F, Rodriguez AM, Boon T, Cerottini JC. cDNA and protein characterization of human MAGE-10. International Journal of Cancer. 82: 901-7. PMID 10446460 DOI: 10.1002/(SICI)1097-0215(19990909)82:6<901::AID-IJC21>3.0.CO;2-X |
0.171 |
|
| 1999 |
Brändle D, Bilsborough J, Rülicke T, Uyttenhove C, Boon T, Van den Eynde BJ. The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. European Journal of Immunology. 28: 4010-9. PMID 9862337 DOI: 10.1002/(SICI)1521-4141(199812)28:12<4010::AID-IMMU4010>3.0.CO;2-5 |
0.171 |
|
| 1995 |
Brichard VG, Warnier G, Van Pel A, Morlighem G, Lucas S, Boon T. Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815. European Journal of Immunology. 25: 664-71. PMID 7705394 DOI: 10.1002/eji.1830250306 |
0.171 |
|
| 2006 |
Sun Z, Lethé B, Zhang Y, Russo V, Colau D, Stroobant V, Boon T, van der Bruggen P. A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors. Cancer Immunology, Immunotherapy : Cii. 55: 644-52. PMID 16187088 DOI: 10.1007/S00262-005-0066-X |
0.17 |
|
| 2003 |
Zhang Y, Chaux P, Stroobant V, Eggermont AM, Corthals J, Maillère B, Thielemans K, Marchand M, Boon T, Van Der Bruggen P. A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. Journal of Immunology (Baltimore, Md. : 1950). 171: 219-25. PMID 12817001 DOI: 10.4049/Jimmunol.171.1.219 |
0.168 |
|
| 1986 |
Van Snick J, De Plaen E, Boon T. A neomycin-resistant cell line for improved production of monoclonal antibodies to cell surface antigens. European Journal of Immunology. 15: 1151-3. PMID 3877638 DOI: 10.1002/eji.1830151116 |
0.167 |
|
| 1993 |
Wölfel T, Hauer M, Klehmann E, Brichard V, Ackermann B, Knuth A, Boon T, Meyer Zum Büschenfelde KH. Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL). International Journal of Cancer. 55: 237-44. PMID 7690346 DOI: 10.1002/ijc.2910550212 |
0.165 |
|
| 1995 |
Grohmann U, Bianchi R, Fioretti MC, Fallarino F, Binaglia L, Uyttenhove C, Van Pel A, Boon T, Puccetti P. CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide. European Journal of Immunology. 25: 2797-802. PMID 7589074 DOI: 10.1002/eji.1830251013 |
0.165 |
|
| 2002 |
Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T. Tumor-specific shared antigenic peptides recognized by human T cells. Immunological Reviews. 188: 51-64. PMID 12445281 DOI: 10.1034/J.1600-065X.2002.18806.X |
0.165 |
|
| 1989 |
Boon T, Van Pel A. T cell-recognized antigenic peptides derived from the cellular genome are not protein degradation products but can be generated directly by transcription and translation of short subgenic regions. A hypothesis. Immunogenetics. 29: 75-9. PMID 2783681 DOI: 10.1007/BF00395854 |
0.164 |
|
| 1983 |
Van Pel A, Vessière F, Boon T. Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis. The Journal of Experimental Medicine. 157: 1992-2001. PMID 6602203 DOI: 10.1084/jem.157.6.1992 |
0.163 |
|
| 1995 |
Boël P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T, van der Bruggen P. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 2: 167-75. PMID 7895173 DOI: 10.1016/S1074-7613(95)80053-0 |
0.162 |
|
| 1999 |
Fallarino F, Uyttenhove C, Boon T, Gajewski TF. Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12. International Journal of Cancer. 80: 324-33. PMID 9935218 DOI: 10.1002/(SICI)1097-0215(19990118)80:2<324::AID-IJC25>3.0.CO;2-D |
0.162 |
|
| 1992 |
Van Pel A, Warnier G, Van den Eynde B, Lethé B, Lurquin C, Boon T. Tum- antigens, TSTA, and T cell immune surveillance. Annals of the New York Academy of Sciences. 636: 43-51. PMID 1793230 DOI: 10.1111/j.1749-6632.1991.tb33437.x |
0.162 |
|
| 1998 |
Fisch P, Meuer E, Pende D, Rothenfusser S, Viale O, Kock S, Ferrone S, Fradelizi D, Klein G, Moretta L, Rammensee HG, Boon T, Coulie P, van der Bruggen P. Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human Vgamma9/Vdelta2 T cells in tumor immunity. European Journal of Immunology. 27: 3368-79. PMID 9464825 DOI: 10.1002/Eji.1830271236 |
0.161 |
|
| 1985 |
Vessière-Louveaux F, Darville M, Knuth A, Boon T. Use of irradiated mouse fibroblasts to improve the cloning and adaptation to culture of human melanoma cells. International Journal of Cancer. 35: 231-5. PMID 3972469 DOI: 10.1002/ijc.2910350215 |
0.16 |
|
| 1982 |
Van Pel A, Boon T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proceedings of the National Academy of Sciences of the United States of America. 79: 4718-22. PMID 6981814 DOI: 10.1073/pnas.79.15.4718 |
0.16 |
|
| 2005 |
Zhang Y, Sun Z, Nicolay H, Meyer RG, Renkvist N, Stroobant V, Corthals J, Carrasco J, Eggermont AM, Marchand M, Thielemans K, Wölfel T, Boon T, van der Bruggen P. Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein. Journal of Immunology (Baltimore, Md. : 1950). 174: 2404-11. PMID 15699177 DOI: 10.4049/Jimmunol.174.4.2404 |
0.16 |
|
| 1996 |
De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proceedings of the National Academy of Sciences of the United States of America. 93: 7149-53. PMID 8692960 DOI: 10.1073/pnas.93.14.7149 |
0.159 |
|
| 1999 |
De Smet C, Lurquin C, Lethé B, Martelange V, Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Molecular and Cellular Biology. 19: 7327-35. PMID 10523621 DOI: 10.1128/MCB.19.11.7327 |
0.158 |
|
| 1993 |
Wallny HJ, Deres K, Faath S, Jung G, Van Pel A, Boon T, Rammensee HG. Identification and quantification of a naturally presented peptide as recognized by cytotoxic T lymphocytes specific for an immunogenic tumor variant. International Immunology. 4: 1085-90. PMID 1283332 DOI: 10.1093/Intimm/4.10.1085 |
0.158 |
|
| 1983 |
Van Snick J, Maryanski J, Van Pel A, Parmiani G, Boon T. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. V. H-2 associativity of variant-specific antigens. European Journal of Immunology. 12: 905-8. PMID 6818041 DOI: 10.1002/eji.1830121102 |
0.158 |
|
| 1995 |
De Backer O, Verheyden AM, Martin B, Godelaine D, De Plaen E, Brasseur R, Avner P, Boon T. Structure, chromosomal location, and expression pattern of three mouse genes homologous to the human MAGE genes. Genomics. 28: 74-83. PMID 7590750 DOI: 10.1006/geno.1995.1108 |
0.156 |
|
| 1994 |
van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boël P, De Smet C, Traversari C, Townsend A, Boon T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. European Journal of Immunology. 24: 3038-43. PMID 7805731 DOI: 10.1002/Eji.1830241218 |
0.155 |
|
| 1997 |
Uyttenhove C, Godfraind C, Lethé B, Amar-Costesec A, Renauld JC, Gajewski TF, Duffour MT, Warnier G, Boon T, Van den Eynde BJ. The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. International Journal of Cancer. Journal International Du Cancer. 70: 349-56. PMID 9033639 DOI: 10.1002/(SICI)1097-0215(19970127)70:3<349::AID-IJC17>3.0.CO;2-A |
0.154 |
|
| 1992 |
Coulie PG, Somville M, Lehmann F, Hainaut P, Brasseur F, Devos R, Boon T. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. International Journal of Cancer. 50: 289-97. PMID 1730522 DOI: 10.1002/ijc.2910500220 |
0.154 |
|
| 1994 |
Puccetti P, Bianchi R, Fioretti MC, Ayroldi E, Uyttenhove C, Van Pel A, Boon T, Grohmann U. Use of a skin test assay to determine tumor-specific CD8+ T cell reactivity. European Journal of Immunology. 24: 1446-52. PMID 8206103 DOI: 10.1002/eji.1830240631 |
0.154 |
|
| 1998 |
Lethé B, Lucas S, Michaux L, De Smet C, Godelaine D, Serrano A, De Plaen E, Boon T. LAGE-1, a new gene with tumor specificity. International Journal of Cancer. 76: 903-8. PMID 9626360 DOI: 10.1002/(SICI)1097-0215(19980610)76:6<903::AID-IJC22>3.0.CO;2-1 |
0.154 |
|
| 2002 |
Zhang Y, Stroobant V, Russo V, Boon T, van der Bruggen P. A MAGE-A4 peptide presented by HLA-B37 is recognized on human tumors by cytolytic T lymphocytes. Tissue Antigens. 60: 365-71. PMID 12492812 DOI: 10.1034/J.1399-0039.2002.600503.X |
0.153 |
|
| 1995 |
Coulie PG, Lehmann F, Lethé B, Herman J, Lurquin C, Andrawiss M, Boon T. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proceedings of the National Academy of Sciences of the United States of America. 92: 7976-80. PMID 7644523 DOI: 10.1073/pnas.92.17.7976 |
0.153 |
|
| 1982 |
Van Snick J, Uyttenhove C, Van Pel A, Boon T. Stimulation of cytolytic T lymphocytes by azaguanine-resistant mouse tumor cells in selective HAT medium. Journal of Immunological Methods. 46: 321-6. PMID 6796623 DOI: 10.1016/0022-1759(81)90317-3 |
0.153 |
|
| 2000 |
Van Pel A, De Plaen E, Duffour MT, Warnier G, Uyttenhove C, Perricaudet M, Boon T. Induction of cytolytic T lymphocytes by immunization of mice with an adenovirus containing a mouse homolog of the human MAGE-A genes Cancer Immunology, Immunotherapy. 49: 593-602. PMID 11225990 DOI: 10.1007/s002620000141 |
0.152 |
|
| 2002 |
Bilsborough J, Uyttenhove C, Colau D, Bousso P, Libert C, Weynand B, Boon T, van den Eynde BJ. TNF-mediated toxicity after massive induction of specific CD8+ T cells following immunization of mice with a tumor-specific peptide. Journal of Immunology (Baltimore, Md. : 1950). 169: 3053-60. PMID 12218121 |
0.151 |
|
| 1996 |
Herman J, Van Der Bruggen P, Luescher IF, Mandruzzato S, Romero P, Thonnard J, Fleischhauer K, Boon T, Coulie PG. A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3 Immunogenetics. 43: 377-383. PMID 8606058 DOI: 10.1007/BF02199806 |
0.151 |
|
| 2002 |
Schiavetti F, Thonnard J, Colau D, Boon T, Coulie PG. A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Research. 62: 5510-6. PMID 12359761 |
0.15 |
|
| 1999 |
De Plaen E, De Backer O, Arnaud D, Bonjean B, Chomez P, Martelange V, Avner P, Baldacci P, Babinet C, Hwang SY, Knowles B, Boon T. A new family of mouse genes homologous to the human MAGE genes. Genomics. 55: 176-84. PMID 9933564 DOI: 10.1006/geno.1998.5638 |
0.149 |
|
| 1996 |
Gaugler B, Brouwenstijn N, Vantomme V, Szikora JP, Van der Spek CW, Patard JJ, Boon T, Schrier P, Van den Eynde BJ. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics. 44: 323-30. PMID 8781117 DOI: 10.1007/BF02602776 |
0.149 |
|
| 1985 |
Van Pel A, De Plaen E, Boon T. Selection of highly transfectable variant from mouse mastocytoma P815. Somatic Cell and Molecular Genetics. 11: 467-75. PMID 3929396 DOI: 10.1007/BF01534840 |
0.148 |
|
| 1993 |
Chambost H, Brasseur F, Coulie P, de Plaen E, Stoppa AM, Baume D, Mannoni P, Boon T, Maraninchi D, Olive D. A tumour-associated antigen expression in human haematological malignancies. British Journal of Haematology. 84: 524-6. PMID 8217804 DOI: 10.1111/j.1365-2141.1993.tb03111.x |
0.148 |
|
| 2005 |
Zammatteo N, Davril C, Brasseur F, Hamels S, De Plaen E, Boon T, Remacle J. Unambiguous identification of the expressed MAGE-A genes on a DNA microarray. Clinical Chemistry. 51: 2420-1. PMID 16306117 DOI: 10.1373/clinchem.2005.057372 |
0.148 |
|
| 2002 |
Zammatteo N, Lockman L, Brasseur F, De Plaen E, Lurquin C, Lobert PE, Hamels S, Boon T, Remacle J. DNA microarray to monitor the expression of MAGE-A genes. Clinical Chemistry. 48: 25-34. PMID 11751535 |
0.146 |
|
| 1982 |
Maryanski JL, Boon T. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones. European Journal of Immunology. 12: 406-12. PMID 6178608 DOI: 10.1002/eji.1830120509 |
0.145 |
|
| 1994 |
De Smet C, Lurquin C, van der Bruggen P, De Plaen E, Brasseur F, Boon T. Sequence and expression pattern of the human MAGE2 gene. Immunogenetics. 39: 121-9. PMID 8276455 DOI: 10.1007/BF00188615 |
0.145 |
|
| 1997 |
Leth?? B, van der Bruggen P, Brasseur F, Boon T. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte Melanoma Research. 7: S89. DOI: 10.1097/00008390-199708001-00013 |
0.144 |
|
| 1994 |
Weynants P, Lethé B, Brasseur F, Marchand M, Boon T. Expression of mage genes by non-small-cell lung carcinomas. International Journal of Cancer. 56: 826-9. PMID 8119772 DOI: 10.1002/ijc.2910560612 |
0.143 |
|
| 2005 |
Zhang Y, Renkvist N, Sun Z, Schuler-Thurner B, Glaichenhaus N, Schuler G, Boon T, van der Bruggen P, Colau D. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells. European Journal of Immunology. 35: 1066-75. PMID 15756643 DOI: 10.1002/Eji.200425847 |
0.143 |
|
| 1998 |
van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, Olive D, Boon T, Coulie PG. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. British Journal of Haematology. 102: 1376-9. PMID 9753074 DOI: 10.1046/j.1365-2141.1998.00982.x |
0.143 |
|
| 2001 |
Schultz ES, Zhang Y, Knowles R, Tine J, Traversari C, Boon T, Van Der Bruggen P. A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes Tissue Antigens. 57: 103-109. PMID 11260504 DOI: 10.1034/J.1399-0039.2001.057002103.X |
0.141 |
|
| 2001 |
Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M, Dorval T, Brichard V, Boon T. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proceedings of the National Academy of Sciences of the United States of America. 98: 10290-5. PMID 11517302 DOI: 10.1073/pnas.161260098 |
0.141 |
|
| 2007 |
van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde BJ, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Journal of Immunology (Baltimore, Md. : 1950). 178: 2617-21. PMID 17312099 |
0.141 |
|
| 2006 |
Takenoyama M, Baurain JF, Yasuda M, So T, Sugaya M, Hanagiri T, Sugio K, Yasumoto K, Boon T, Coulie PG. A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma. International Journal of Cancer. Journal International Du Cancer. 118: 1992-7. PMID 16287085 DOI: 10.1002/ijc.21594 |
0.141 |
|
| 1988 |
Weynants P, Wauters P, Coulie PG, Van den Eynde B, Symann M, Boon T. Cytolytic response of human T cells against allogeneic small cell lung carcinoma treated with interferon gamma. Cancer Immunology, Immunotherapy : Cii. 27: 228-32. PMID 2846175 DOI: 10.1007/BF00205444 |
0.14 |
|
| 2005 |
Brenner C, Deplus R, Didelot C, Loriot A, Viré E, De Smet C, Gutierrez A, Danovi D, Bernard D, Boon T, Pelicci PG, Amati B, Kouzarides T, de Launoit Y, Di Croce L, et al. Myc represses transcription through recruitment of DNA methyltransferase corepressor. The Embo Journal. 24: 336-46. PMID 15616584 DOI: 10.1038/Sj.Emboj.7600509 |
0.139 |
|
| 2003 |
Kobayashi T, Lonchay C, Colau D, Demotte N, Boon T, van der Bruggen P. New MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A1 tumor cells. Tissue Antigens. 62: 426-32. PMID 14617050 DOI: 10.1034/j.1399-0039.2003.00123.x |
0.139 |
|
| 1999 |
Duffour MT, Chaux P, Lurquin C, Cornelis G, Boon T, van der Bruggen P. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. European Journal of Immunology. 29: 3329-37. PMID 10540345 DOI: 10.1002/(Sici)1521-4141(199910)29:10<3329::Aid-Immu3329>3.0.Co;2-7 |
0.139 |
|
| 1972 |
Boon T. Inactivation of ribosomes in vitro by colicin E 3 and its mechanism of action Proceedings of the National Academy of Sciences of the United States of America. 69: 549-552. PMID 4551976 |
0.138 |
|
| 1997 |
Visseren MJ, van der Burg SH, van der Voort EI, Brandt RM, Schrier PI, van der Bruggen P, Boon T, Melief CJ, Kast WM. Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product. International Journal of Cancer. 73: 125-30. PMID 9334819 DOI: 10.1002/(Sici)1097-0215(19970926)73:1<125::Aid-Ijc19>3.0.Co;2-F |
0.138 |
|
| 1994 |
De Plaen E, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethé B, Lurquin C, Chomez P, De Backer O, Boon T, Arden K, Cavenee W, Brasseur R. Structure, chromosomal localization, and expression of 12 genes of the MAGE family Immunogenetics. 40: 360-369. PMID 7927540 DOI: 10.1007/Bf01246677 |
0.137 |
|
| 2004 |
Ma W, Germeau C, Vigneron N, Maernoudt AS, Morel S, Boon T, Coulie PG, Van den Eynde BJ. Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2. International Journal of Cancer. Journal International Du Cancer. 109: 698-702. PMID 14999777 DOI: 10.1002/ijc.20038 |
0.136 |
|
| 2011 |
Ma W, Vigneron N, Chapiro J, Stroobant V, Germeau C, Boon T, Coulie PG, Van den Eynde BJ. A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy. International Journal of Cancer. Journal International Du Cancer. 129: 2427-34. PMID 21207413 DOI: 10.1002/ijc.25911 |
0.135 |
|
| 1997 |
Weynants P, Marchand M, Baurain J, Deloos M, Boon T, Coulie P. 572 Production of cytolytic T cell (CTL) clones directed against autologous small cell and non-small cell lung cancer cell lines Lung Cancer. 18: 147. DOI: 10.1016/S0169-5002(97)89952-7 |
0.134 |
|
| 1993 |
Coulie P, Weynants P, Muller C, Lehmann F, Herman J, Baurain JF, Boon T. Genes coding for antigens recognized on human tumors by autologous cytolytic T lymphocytes. Annals of the New York Academy of Sciences. 690: 113-9. PMID 8368730 DOI: 10.1111/j.1749-6632.1993.tb44001.x |
0.133 |
|
| 1998 |
Chaux P, Vantomme V, Coulie P, Boon T, van der Bruggen P. Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. International Journal of Cancer. 77: 538-42. PMID 9679755 DOI: 10.1002/(SICI)1097-0215(19980812)77:4<538::AID-IJC11>3.0.CO;2-2 |
0.133 |
|
| 2000 |
Sugaya M, Takenoyama M, Yasuda M, So T, Eifuku R, Yoshimatsu T, Oyama T, Coulie P, Boon T, Yasumoto K. Identification of a mutated tumor-specific peptide recognized by HLA-B52-restricted cytotoxic T lymphocytes on a squamous cell carcinoma of the lung Lung Cancer. 29: 175-176. DOI: 10.1016/S0169-5002(00)80589-9 |
0.133 |
|
| 2003 |
Vantomme V, Boël P, De Plaen E, Boon T, van der Bruggen P. A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16. Cancer Immunity. 3: 17. PMID 14664500 |
0.132 |
|
| 2007 |
Godelaine D, Carrasco J, Brasseur F, Neyns B, Thielemans K, Boon T, Van Pel A. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44. Cancer Immunology, Immunotherapy : Cii. 56: 753-9. PMID 17096150 DOI: 10.1007/s00262-006-0244-5 |
0.131 |
|
| 2005 |
Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dréno B, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, Ritter G, Lethé B, Godelaine D, ... ... Boon T, et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. International Journal of Cancer. Journal International Du Cancer. 117: 596-604. PMID 15945101 DOI: 10.1002/Ijc.21264 |
0.129 |
|
| 1986 |
Knuth A, van Pel A, Meyer zum Bueschenfelde K-, Boon T. T-lymphocytotoxicity in malignant melanoma: Induction with autologous mutagenized tumor cell clones Journal of Cancer Research and Clinical Oncology. 111: S147-S147. DOI: 10.1007/BF02580358 |
0.129 |
|
| 1995 |
Van Pel A, van der Bruggen P, Coulie PG, Brichard VG, Lethé B, van den Eynde B, Uyttenhove C, Renauld JC, Boon T. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunological Reviews. 145: 229-50. PMID 7590828 DOI: 10.1111/j.1600-065X.1995.tb00084.x |
0.128 |
|
| 1995 |
De Smet C, Courtois SJ, Faraoni I, Lurquin C, Szikora JP, De Backer O, Boon T. Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene. Immunogenetics. 42: 282-90. PMID 7672823 DOI: 10.1007/BF00176446 |
0.128 |
|
| 2005 |
Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, Vigneron N, Brasseur F, Lethé B, De Plaen E, Velu T, Boon T, Coulie PG. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. The Journal of Experimental Medicine. 201: 241-8. PMID 15657293 DOI: 10.1084/jem.20041379 |
0.126 |
|
| 1995 |
Van Pel A, van der Bruggen P, Van den Eynde B, Brichard V, Coulie P, De Plaen E, Guilloux Y, Lucas S, Boon T. 605 Tumor antigens recognized by cytolytic T lymphocytes European Journal of Cancer. 31: S128. DOI: 10.1016/0959-8049(95)95859-5 |
0.125 |
|
| 2004 |
Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D, Lucas S, Van Pel A, Thielemans K, van Baren N, Boon T. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proceedings of the National Academy of Sciences of the United States of America. 101: 14631-8. PMID 15452345 DOI: 10.1073/pnas.0405743101 |
0.124 |
|
| 1998 |
Schneider J, Brichard V, Boon T, Meyer zum Büschenfelde KH, Wölfel T. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1. International Journal of Cancer. 75: 451-8. PMID 9455808 DOI: 10.1002/(SICI)1097-0215(19980130)75:3<451::AID-IJC20>3.0.CO;2-A |
0.124 |
|
| 2001 |
Van Leuven F, Thiry E, Lambrechts M, Stas L, Boon T, Bruynseels K, Muls E, Descamps O. Sequencing of the coding exons of the LRP1 and LDLR genes on individual DNA samples reveals novel mutations in both genes. Atherosclerosis. 154: 567-77. PMID 11257257 DOI: 10.1016/S0021-9150(00)00657-2 |
0.123 |
|
| 1972 |
Boon T. Inactivation of ribosomes in vitro by colicin E 3 . Proceedings of the National Academy of Sciences of the United States of America. 68: 2421-5. PMID 4944624 DOI: 10.1073/pnas.68.10.2421 |
0.122 |
|
| 1999 |
Boon T. Tumor antigens recognised by T lymphocytes European Journal of Cancer. 35: S216. DOI: 10.1016/s0959-8049(99)81271-4 |
0.122 |
|
| 1996 |
Van den Eynde B, Gaugler B, van der Bruggen P, Coulie P, Brichard V, Boon T. Human tumour antigens recognized by T-cells: perspectives for new cancer vaccines. Biochemical Society Transactions. 23: 681-6. PMID 8566443 DOI: 10.1042/bst0230681 |
0.118 |
|
| 2004 |
De Smet C, Loriot A, Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells. Molecular and Cellular Biology. 24: 4781-90. PMID 15143172 DOI: 10.1128/MCB.24.11.4781-4790.2004 |
0.117 |
|
| 2004 |
Vialle-Castellano A, Laduron S, De Plaen E, Jost E, Dupont S, Ameye G, Michaux L, Coulie P, Olive D, Boon T, van Baren N. A gene expressed exclusively in acute B lymphoblastic leukemias. Genomics. 83: 85-94. PMID 14667812 DOI: 10.1016/S0888-7543(03)00209-X |
0.117 |
|
| 2007 |
So T, Hanagiri T, Chapiro J, Colau D, Brasseur F, Yasumoto K, Boon T, Coulie PG. Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules. Cancer Immunology, Immunotherapy : Cii. 56: 259-69. PMID 16758204 DOI: 10.1007/s00262-006-0186-y |
0.117 |
|
| 1986 |
MEYTS P, HALLEZ S, GU JL, MERCHEZ M, ECONOMIDIS I, ROUSSEAU GG, SNICK J, SPINEL C, SQUIFFLET JP, RAVOET AM, BRUYERE M, WILLARD K, VESSIERE F, LEMOINE C, BOON T, et al. Aberrant Expression of HLA-DR Determinants on Human Thyroid Cells Treated with Phytohemagglutinin and ?-Interferon and on Human Melanoma Cells Demonstration with a Binding Assay Using a New Potent125I-Monoclonal Antibody against the HLA-DR ?-Chain (MAb 03-D7) Annals of the New York Academy of Sciences. 475: 359-360. DOI: 10.1111/j.1749-6632.1986.tb20893.x |
0.116 |
|
| 1997 |
Weynants P, Marchand M, Brasseur F, Boon T. 615 Expression by 104 non-small cell lung carcinomas of defined antigens recognized by T lymphocytes: Perspectives for anti-cancer vaccines Lung Cancer. 18: 158. DOI: 10.1016/S0169-5002(97)89995-3 |
0.116 |
|
| 2000 |
Heidecker L, Brasseur F, Probst-Kepper M, Guéguen M, Boon T, Van den Eynde BJ. Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12. Journal of Immunology (Baltimore, Md. : 1950). 164: 6041-5. PMID 10820289 DOI: 10.4049/jimmunol.164.11.6041 |
0.115 |
|
| 2008 |
Carrasco J, Van Pel A, Neyns B, Lethé B, Brasseur F, Renkvist N, van der Bruggen P, van Baren N, Paulus R, Thielemans K, Boon T, Godelaine D. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. Journal of Immunology (Baltimore, Md. : 1950). 180: 3585-93. PMID 18292586 |
0.115 |
|
| 1994 |
Coulie PG, Brichard V, Van Pel A, Wölfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP, Renauld JC, Boon T. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. The Journal of Experimental Medicine. 180: 35-42. PMID 8006593 DOI: 10.1084/jem.180.1.35 |
0.114 |
|
| 2000 |
Schultz ES, Lethe B, Cambiaso CL, Van Snick J, Chaux P, Corthals J, Heirman C, Thielemans K, Boon T, Van der Bruggen P. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes Cancer Research. 60: 6272-6275. PMID 11103782 |
0.114 |
|
| 2002 |
Coulie PG, Karanikas V, Lurquin C, Colau D, Connerotte T, Hanagiri T, Van Pel A, Lucas S, Godelaine D, Lonchay C, Marchand M, Van Baren N, Boon T. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunological Reviews. 188: 33-42. PMID 12445279 DOI: 10.1034/j.1600-065X.2002.18804.x |
0.113 |
|
| 2001 |
Probst-Kepper M, Stroobant V, Kridel R, Gaugler B, Landry C, Brasseur F, Cosyns JP, Weynand B, Boon T, Van Den Eynde BJ. An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes Journal of Experimental Medicine. 193: 1189-1198. PMID 11369790 DOI: 10.1084/jem.193.10.1189 |
0.112 |
|
| 1999 |
Marchand M, van Baren N, Weynants P, Brichard V, Dréno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Liénard D, Beauduin M, Dietrich PY, ... ... Boon T, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. International Journal of Cancer. 80: 219-30. PMID 9935203 DOI: 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S |
0.112 |
|
| 1999 |
Serrano A, Lethé B, Delroisse JM, Lurquin C, De Plaen E, Brasseur F, Rimoldi D, Boon T. Quantitative evaluation of the expression of MAGE genes in tumors by limiting dilution of cDNA libraries. International Journal of Cancer. Journal International Du Cancer. 83: 664-9. PMID 10521804 DOI: 10.1002/(SICI)1097-0215(19991126)83:5<664::AID-IJC16>3.0.CO;2-V |
0.111 |
|
| 1994 |
Wölfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Büschenfelde KH, Boon T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. European Journal of Immunology. 24: 759-64. PMID 8125142 DOI: 10.1002/eji.1830240340 |
0.11 |
|
| 1984 |
Lambotte P, Van Snick J, Boon T. Partial purification of a membrane glycoprotein antigen by high-pressure size-exclusion chromatography without loss of antigenicity. Journal of Chromatography. 297: 139-45. PMID 6490754 DOI: 10.1016/S0021-9673(01)89037-3 |
0.11 |
|
| 1997 |
Coulie PG, Van den Eynde BJ, van der Bruggen P, Van Pel A, Boon T. Antigens recognized by T-lymphocytes on human tumours. Biochemical Society Transactions. 25: 544-8. PMID 9191153 DOI: 10.1042/bst0250544 |
0.11 |
|
| 2003 |
Karanikas V, Lurquin C, Colau D, van Baren N, De Smet C, Lethé B, Connerotte T, Corbière V, Demoitié MA, Liénard D, Dréno B, Velu T, Boon T, Coulie PG. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. Journal of Immunology (Baltimore, Md. : 1950). 171: 4898-904. PMID 14568971 |
0.109 |
|
| 2009 |
François V, Ottaviani S, Renkvist N, Stockis J, Schuler G, Thielemans K, Colau D, Marchand M, Boon T, Lucas S, van der Bruggen P. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Research. 69: 4335-45. PMID 19435913 DOI: 10.1158/0008-5472.CAN-08-3726 |
0.109 |
|
| 2003 |
Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Medicine. 9: 1269-74. PMID 14502282 DOI: 10.1038/nm934 |
0.109 |
|
| 2004 |
Laduron S, Deplus R, Zhou S, Kholmanskikh O, Godelaine D, De Smet C, Hayward SD, Fuks F, Boon T, De Plaen E. MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Research. 32: 4340-50. PMID 15316101 DOI: 10.1093/Nar/Gkh735 |
0.109 |
|
| 1997 |
De Plaen E, Naerhuyzen B, De Smet C, Szikora JP, Boon T. Alternative promoters of gene MAGE4a. Genomics. 40: 305-13. PMID 9119398 DOI: 10.1006/geno.1996.4566 |
0.108 |
|
| 2006 |
Carrasco J, Godelaine D, Van Pel A, Boon T, van der Bruggen P. CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation. Blood. 108: 2897-905. PMID 16857986 DOI: 10.1182/blood-2005-11-007237 |
0.108 |
|
| 1996 |
Chomez P, Williams R, De Backer O, Boon T, Vennström B. The SMAGE gene family is expressed in post-meiotic spermatids during mouse germ cell differentiation. Immunogenetics. 43: 97-100. PMID 8537132 DOI: 10.1007/BF00186613 |
0.107 |
|
| 1995 |
Boon T, Van Der Bruggen P, Brichard V, Van Pel A, Coulie P, Gaugler B, Van Den Eynde B, De Plaen E. 995 Genes coding for tumor rejection antigens European Journal of Cancer. 31: S207-S208. DOI: 10.1016/0959-8049(95)96243-7 |
0.107 |
|
| 2004 |
Corbière V, Nicolay H, Russo V, Stroobant V, Brichard V, Boon T, van der Bruggen P. Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors. Tissue Antigens. 63: 453-7. PMID 15104676 DOI: 10.1111/j.0001-2815.2004.00203.x |
0.107 |
|
| 2006 |
Chapiro J, Claverol S, Piette F, Ma W, Stroobant V, Guillaume B, Gairin JE, Morel S, Burlet-Schiltz O, Monsarrat B, Boon T, Van den Eynde BJ. Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation. Journal of Immunology (Baltimore, Md. : 1950). 176: 1053-61. PMID 16393993 |
0.106 |
|
| 2005 |
Lurquin C, Lethé B, De Plaen E, Corbière V, Théate I, van Baren N, Coulie PG, Boon T. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. The Journal of Experimental Medicine. 201: 249-57. PMID 15657294 DOI: 10.1084/jem.20041378 |
0.105 |
|
| 2006 |
Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annual Review of Immunology. 24: 175-208. PMID 16551247 DOI: 10.1146/annurev.immunol.24.021605.090733 |
0.104 |
|
| 2014 |
Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nature Reviews. Cancer. 14: 135-46. PMID 24457417 DOI: 10.1038/nrc3670 |
0.103 |
|
| 2008 |
Demotte N, Stroobant V, Courtoy PJ, Van Der Smissen P, Colau D, Luescher IF, Hivroz C, Nicaise J, Squifflet JL, Mourad M, Godelaine D, Boon T, van der Bruggen P. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity. 28: 414-24. PMID 18342010 DOI: 10.1016/j.immuni.2008.01.011 |
0.096 |
|
| 2002 |
Schultz ES, Chapiro J, Lurquin C, Claverol S, Burlet-Schiltz O, Warnier G, Russo V, Morel S, Lévy F, Boon T, Van den Eynde BJ, van der Bruggen P. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. The Journal of Experimental Medicine. 195: 391-9. PMID 11854353 DOI: 10.1084/jem.20011974 |
0.095 |
|
| 2000 |
Landry C, Brasseur F, Spagnoli GC, Marbaix E, Boon T, Coulie P, Godelaine D. Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4. International Journal of Cancer. 86: 835-41. PMID 10842198 DOI: 10.1002/(SICI)1097-0215(20000615)86:6<835::AID-IJC12>3.0.CO;2-N |
0.094 |
|
| 2001 |
Chaux P, Lethé B, Van Snick J, Corthals J, Schultz ES, Cambiaso CL, Boon T, Van Bruggen PD. A MAGE-1 peptide recognized on HLA-DR15 by CD4+ T cells European Journal of Immunology. 31: 1910-1916. PMID 11433388 DOI: 10.1002/1521-4141(200106)31:6<1910::AID-IMMU1910>3.0.CO;2-K |
0.093 |
|
| 1997 |
Lurquin C, De Smet C, Brasseur F, Muscatelli F, Martelange V, De Plaen E, Brasseur R, Monaco AP, Boon T. Two members of the human MAGEB gene family located in Xp21.3 are expressed in tumors of various histological origins. Genomics. 46: 397-408. PMID 9441743 DOI: 10.1006/geno.1997.5052 |
0.093 |
|
| 2013 |
Zsákai L, Németh G, Szántai-Kis C, Greff Z, Horváth Z, Szokol B, Baska F, Boon TC, Orfi L, Kéri G. [Developing FGFR inhibitors as potential anti-cancer agents]. Acta Pharmaceutica Hungarica. 83: 47-56. PMID 23926649 |
0.092 |
|
| 2003 |
Godelaine D, Carrasco J, Lucas S, Karanikas V, Schuler-Thurner B, Coulie PG, Schuler G, Boon T, Van Pel A. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. Journal of Immunology (Baltimore, Md. : 1950). 171: 4893-7. PMID 14568970 |
0.092 |
|
| 1994 |
Rimoldi D, Brasseur F, Liénard D, Lethe B, Carrel S, Lejeune FJ, Cerottini J, Boon T, Marchand M. Analysis of MAGE gene expression in melanoma tumor progression Melanoma Research. 4: 47. DOI: 10.1097/00008390-199409001-00108 |
0.091 |
|
| 2005 |
Miyahara Y, Naota H, Wang L, Hiasa A, Goto M, Watanabe M, Kitano S, Okumura S, Takemitsu T, Yuta A, Majima Y, Lemonnier FA, Boon T, Shiku H. Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5581-9. PMID 16061876 DOI: 10.1158/1078-0432.CCR-04-2585 |
0.088 |
|
| 2002 |
Bilsborough J, Panichelli C, Duffour MT, Warnier G, Lurquin C, Schultz ES, Thielemans K, Corthals J, Boon T, van der Bruggen P. A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18. Tissue Antigens. 60: 16-24. PMID 12366779 DOI: 10.1034/j.1399-0039.2002.600103.x |
0.087 |
|
| 2003 |
Loriot A, Boon T, De Smet C. Five new human cancer-germline genes identified among 12 genes expressed in spermatogonia. International Journal of Cancer. Journal International Du Cancer. 105: 371-6. PMID 12704671 DOI: 10.1002/ijc.11104 |
0.085 |
|
| 1997 |
Coulie P, Van der Bruggen P, Van den Eynde B, Marchand M, Boon T. Tumour specific antigens: Perspectives for vaccination European Journal of Cancer. 33: S288. DOI: 10.1016/s0959-8049(97)86209-0 |
0.081 |
|
| 2011 |
Corbière V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Research. 71: 1253-62. PMID 21216894 DOI: 10.1158/0008-5472.CAN-10-2693 |
0.079 |
|
| 2006 |
Loriot A, De Plaen E, Boon T, De Smet C. Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells. The Journal of Biological Chemistry. 281: 10118-26. PMID 16497664 DOI: 10.1074/jbc.M510469200 |
0.077 |
|
| 1992 |
Maryanski JL, Romero P, Van Pel A, Boon T, Salemme FR, Cerottini JC, Corradin G. The identification of tyrosine as a common key residue in unrelated H-2Kd restricted antigenic peptides. International Immunology. 3: 1035-42. PMID 1721832 DOI: 10.1093/intimm/3.10.1035 |
0.076 |
|
| 1994 |
Klein G, Boon T. Tumor immunology: present perspectives. Current Opinion in Immunology. 5: 687-92. PMID 8240730 DOI: 10.1016/0952-7915(93)90122-9 |
0.073 |
|
| 1996 |
Mulcahy KA, Rimoldi D, Brasseur F, Rodgers S, Liénard D, Marchand M, Rennie IG, Murray AK, McIntyre CA, Platts KE, Leyvraz S, Boon T, Rees RC. Infrequent expression of the MAGE gene family in uveal melanomas. International Journal of Cancer. Journal International Du Cancer. 66: 738-42. PMID 8647642 DOI: 10.1002/(SICI)1097-0215(19960611)66:6<738::AID-IJC5>3.0.CO;2-0 |
0.068 |
|
| 2003 |
Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Håkansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AM, Scheibenbogen C, Uiters J, Wanders J, ... ... Boon T, et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. European Journal of Cancer (Oxford, England : 1990). 39: 70-7. PMID 12504661 DOI: 10.1016/S0959-8049(02)00479-3 |
0.068 |
|
| 2012 |
Cipponi A, Mercier M, Seremet T, Baurain JF, Théate I, van den Oord J, Stas M, Boon T, Coulie PG, van Baren N. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Research. 72: 3997-4007. PMID 22850419 DOI: 10.1158/0008-5472.CAN-12-1377 |
0.062 |
|
| 2006 |
Hanagiri T, van Baren N, Neyns B, Boon T, Coulie PG. Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1. Cancer Immunology, Immunotherapy : Cii. 55: 178-84. PMID 16187089 DOI: 10.1007/s00262-005-0063-0 |
0.06 |
|
| 2006 |
Boucquey M, De Plaen E, Locker M, Poliard A, Mouillet-Richard S, Boon T, Kellermann O. Noxp20 and Noxp70, two new markers of early neuronal differentiation, detected in teratocarcinoma-derived neuroectodermic precursor cells. Journal of Neurochemistry. 99: 657-69. PMID 17029606 DOI: 10.1111/j.1471-4159.2006.04093.x |
0.059 |
|
| 2005 |
de Waal EE, Bruins P, Lahpor JR, Steijling JJ, de Kort LM, Boon TA. Chasing the tumor thrombus. Anesthesia and Analgesia. 101: 332. PMID 16037139 DOI: 10.1213/01.ANE.0000158467.63965.AF |
0.059 |
|
| 2004 |
Vigneron N, Stroobant V, Chapiro J, Ooms A, Degiovanni G, Morel S, van der Bruggen P, Boon T, Van den Eynde BJ. An antigenic peptide produced by peptide splicing in the proteasome. Science (New York, N.Y.). 304: 587-90. PMID 15001714 DOI: 10.1126/science.1095522 |
0.059 |
|
| 2003 |
Grimbergen MC, van Swol CF, Jonges TG, Boon TA, van Moorselaar RJ. Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy. European Urology. 44: 51-6. PMID 12814675 DOI: 10.1016/S0302-2838(03)00210-0 |
0.057 |
|
| 2015 |
Bobier C, Boon T, Downward M, Loomes B, Mountford H, Swadi H. Pilot Investigation of the Use and Usefulness of a Sensory Modulation Room in a Child and Adolescent Psychiatric Inpatient Unit Occupational Therapy in Mental Health. 31: 385-401. DOI: 10.1080/0164212X.2015.1076367 |
0.054 |
|
| 2000 |
Spittaels K, Van den Haute C, Van Dorpe J, Geerts H, Mercken M, Bruynseels K, Lasrado R, Vandezande K, Laenen I, Boon T, Van Lint J, Vandenheede J, Moechars D, Loos R, Van Leuven F. Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. The Journal of Biological Chemistry. 275: 41340-9. PMID 11007782 DOI: 10.1074/jbc.M006219200 |
0.054 |
|
| 2002 |
Verhagen PC, Hermans KG, Brok MO, van Weerden WM, Tilanus MG, de Weger RA, Boon TA, Trapman J. Deletion of chromosomal region 6q14-16 in prostate cancer. International Journal of Cancer. Journal International Du Cancer. 102: 142-7. PMID 12385009 DOI: 10.1002/ijc.10677 |
0.054 |
|
| 2002 |
Demotte N, Colau D, Ottaviani S, Godelaine D, Van Pel A, Boon T, van der Bruggen P. A reversible functional defect of CD8+ T lymphocytes involving loss of tetramer labeling. European Journal of Immunology. 32: 1688-97. PMID 12115652 DOI: 10.1002/1521-4141(200206)32:6<1688::AID-IMMU1688>3.0.CO;2-9 |
0.053 |
|
| 2009 |
Stockis J, Fink W, François V, Connerotte T, de Smet C, Knoops L, van der Bruggen P, Boon T, Coulie PG, Lucas S. Comparison of stable human Treg and Th clones by transcriptional profiling. European Journal of Immunology. 39: 869-82. PMID 19224638 DOI: 10.1002/eji.200838807 |
0.052 |
|
| 2011 |
Taher A, Rabb Z, Kuwano J, Deng J, Boon TW. Effect of curing stress and period on the mechanical properties of cement-mixed sand Soils and Foundations. 51: 651-661. DOI: 10.3208/sandf.51.651 |
0.051 |
|
| 2002 |
Derogee M, Bevers RFM, Prins HJ, Jonges TGN, Elbers FH, Boon TA. Testicular microlithiasis, a premaligmant condition: Prevalence, histopathologic findings, and relation to testicular tumor | Testiculaire microlithiasis, een premaligne aandoening: Prevalentie, histopathologische bevindingen en relatie tot testistumor Nederlands Tijdschrift Voor Urologie. 10: 136-142. |
0.05 |
|
| 2001 |
Derogee M, Bevers RFM, Prins HJ, Jonges TGN, Elbers FH, Boon TA. Testicular microlithiasis, a premalignant condition: Prevalence, histopathologic findings, and relation to testicular tumor Urology. 57: 1133-1137. PMID 11377326 DOI: 10.1016/S0090-4295(01)00957-8 |
0.049 |
|
| 2001 |
Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Research. 61: 5544-51. PMID 11454705 |
0.04 |
|
| 2003 |
De Vocht TF, van Venrooij GE, Boon TA. Self-expanding stent insertion for urethral strictures: a 10-year follow-up. Bju International. 91: 627-30. PMID 12699473 DOI: 10.1046/j.1464-410X.2003.04200.x |
0.039 |
|
| 2015 |
Hyder R, Kamel N, Boon TT, Reza F. Mapping of language brain areas in patients with brain tumors Proceedings of the Annual International Conference of the Ieee Engineering in Medicine and Biology Society, Embs. 2015: 626-629. DOI: 10.1109/EMBC.2015.7318440 |
0.033 |
|
| 2003 |
Roshani H, Dabhoiwala NF, Dijkhuis T, Pfaffendorf M, Boon TA, Lamers WH. Pharmacological modulation of ureteral peristalsis in a chronically instrumented conscious pig model. I: Effect of cholinergic stimulation and inhibition. The Journal of Urology. 170: 264-7. PMID 12796701 DOI: 10.1097/01.ju.0000071964.04804.e4 |
0.032 |
|
| 2004 |
Battermann JJ, Boon TA, Moerland MA. Results of permanent prostate brachytherapy, 13 years of experience at a single institution. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 71: 23-8. PMID 15066292 DOI: 10.1016/j.radonc.2004.01.020 |
0.032 |
|
| 2003 |
Boon T, van Baren N. Immunosurveillance against cancer and immunotherapy--synergy or antagonism? The New England Journal of Medicine. 348: 252-4. PMID 12529468 DOI: 10.1056/NEJMe020165 |
0.031 |
|
| 2014 |
Bourdeaux C, Lurquin C, Jacquemart I, Lethé B, Brasseur F, van Baren N, Baurain JF, Dyson J, Van Snick J, Uyttenhove C, Boon T. Local immunostimulation leading to rejection of accepted male skin grafts by female mice as a model for cancer immunotherapy. Proceedings of the National Academy of Sciences of the United States of America. 111: 3502-7. PMID 24550491 DOI: 10.1073/pnas.1401115111 |
0.029 |
|
| 2011 |
Boon T. Medical Film and Television: An Alternative Path to the Cultures of Biomedicine The Oxford Handbook of the History of Medicine. DOI: 10.1093/oxfordhb/9780199546497.013.0034 |
0.028 |
|
| 2001 |
Eckhardt MD, Van Venrooij GEPM, Boon TA. Urethral resistance factor (URA) versus Schäfer's obstruction grade and Abrams-Griffiths (AG) number in the diagnosis of obstructive benign prostatic hyperplasia Neurourology and Urodynamics. 20: 175-185. PMID 11170192 DOI: 10.1002/1520-6777(2001)20:2<175::AID-NAU20>3.0.CO;2-T |
0.028 |
|
| 2001 |
Eckhardt MD, van Venrooij GE, Boon TA. Symptoms and quality of life versus age, prostate volume, and urodynamic parameters in 565 strictly selected men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia Urology. 57: 695-700. PMID 11306383 |
0.027 |
|
| 2003 |
Van Vulpen M, De Leeuw AA, Van De Kamer JB, Kroeze H, Boon TA, Wárlám-Rodenhuis CC, Lagendijk JJ, Battermann JJ. Comparison of intra-luminal versus intra-tumoural temperature measurements in patients with locally advanced prostate cancer treated with the coaxial TEM system: report of a feasibility study. International Journal of Hyperthermia : the Official Journal of European Society For Hyperthermic Oncology, North American Hyperthermia Group. 19: 481-97. PMID 12944164 DOI: 10.1080/0265673031000096327 |
0.027 |
|
| 2003 |
van Venrooij GE, van Melick HH, Boon TA. Comparison of outcomes of transurethral prostate resection in urodynamicallyobstructed versus selected urodynamicallyunobstructed or equivocal men. Urology. 62: 672-6. PMID 14550441 DOI: 10.1016/S0090-4295(03)00511-9 |
0.026 |
|
| 2001 |
Eckhardt MD, van Venrooij GE, Boon TA. Symptoms, prostate volume, and urodynamic findings in elderly male volunteers without and with LUTS and in patients with LUTS suggestive of benign prostatic hyperplasia. Urology. 58: 966-71. PMID 11744470 DOI: 10.1016/S0090-4295(01)01413-3 |
0.025 |
|
| 2002 |
van Venrooij GE, Eckhardt MD, Gisolf KW, Boon TA. Data from frequency-volume charts versus filling cystometric estimated capacities and prevalence of instability in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Neurourology and Urodynamics. 21: 106-11. PMID 11857662 DOI: 10.1002/nau.10049 |
0.025 |
|
| 2008 |
van Venrooij GE, van Melick HH, Eckhardt MD, Boon TA. Diagnostic and predictive value of voiding diary data versus prostate volume, maximal free urinary flow rate, and Abrams-Griffiths number in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 71: 469-74. PMID 18342189 DOI: 10.1016/j.urology.2007.11.033 |
0.025 |
|
| 2014 |
Lutterbach-Penna RA, Kalume-Brigido M, Morag Y, Boon T, Jacobson JA, Fessell DP. Ultrasound of the thigh: focal, compartmental, or comprehensive examination? Ajr. American Journal of Roentgenology. 203: 1085-92. PMID 25341149 DOI: 10.2214/AJR.13.12286 |
0.025 |
|
| 2007 |
Boormans JL, van Venrooij GE, Boon TA. Invasively estimated International Continence Society obstruction classification versus noninvasively assessed bladder outlet obstruction probability in treatment recommendation for LUTS suggestive of BPH. Urology. 69: 485-90. PMID 17382150 DOI: 10.1016/j.urology.2006.10.039 |
0.025 |
|
| 2001 |
Van Venrooij GEPM, Eckhardt MD, Gisolf KWH, Boon TA. Data from frequency-volume charts versus symptom scores and quality of life score in men with lower urinary tract symptoms due to benign prostatic hyperplasia European Urology. 39: 42-47. PMID 11173938 DOI: 10.1159/000052411 |
0.025 |
|
| 2015 |
Boon T. 'The televising of science is a process of television': establishing Horizon, 1962-1967. British Journal For the History of Science. 48: 87-121. PMID 25833799 DOI: 10.1017/S0007087414000405 |
0.024 |
|
| 2003 |
van Melick HH, van Venrooij GE, Eckhardt MD, Boon TA. A randomized controlled trial comparing transurethral resection of the prostate, contact laser prostatectomy and electrovaporization in men with benign prostatic hyperplasia: analysis of subjective changes, morbidity and mortality. The Journal of Urology. 169: 1411-6. PMID 12629374 DOI: 10.1097/01.ju.0000054657.59200.97 |
0.024 |
|
| 2002 |
Van Venrooij GE, Eckhardt MD, Boon TA. Data from frequency-volume charts versus maximum free flow rate, residual volume, and voiding cystometric estimated urethral obstruction grade and detrusor contractility grade in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Neurourology and Urodynamics. 21: 450-6. PMID 12232879 DOI: 10.1002/nau.10032 |
0.023 |
|
| 2002 |
Van Melick HH, Van Venrooij GE, Eckhardt MD, Boon TA. A randomized controlled trial comparing transurethral resection of the prostate, contact laser prostatectomy and electrovaporization in men with benign prostatic hyperplasia: urodynamic effects. The Journal of Urology. 168: 1058-62. PMID 12187222 DOI: 10.1097/01.ju.0000026655.95081.cb |
0.022 |
|
| 2001 |
Eckhardt MD, van Venrooij GE, Boon TA. Interactions between prostate volume, filling cystometric estimated parameters, and data from pressure-flow studies in 565 men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Neurourology and Urodynamics. 20: 579-90. PMID 11574935 DOI: 10.1002/nau.1010 |
0.022 |
|
| 2002 |
Boormans JL, Van Venrooij GEPM, Boon TA, De Kort LMO. The diagnostic value of the BOON versus the Schäfer-classification in men older than 50 years with LUTS due to benign prostatic hyperplasia | De diagnostische waarde van het BOON ten opzichte van de Schäfer-graad bij mannen ouder dan 50 jaar met 'lower urinary tract symptoms' passend bij benigne prostaat hyperplasie Nederlands Tijdschrift Voor Urologie. 10: 127-133. |
0.022 |
|
| 2004 |
van Venrooij GE, Eckhardt MD, Boon TA. Noninvasive assessment of prostatic obstruction in elderly men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Urology. 63: 476-80. PMID 15028441 DOI: 10.1016/j.urology.2003.10.021 |
0.021 |
|
| 2002 |
Verhagen PC, Tilanus MG, de Weger RA, van Moorselaar RJ, van den Tweel JG, Boon TA. Prognostic factors in localised prostate cancer with emphasis on the application of molecular techniques. European Urology. 41: 363-71. PMID 12074805 DOI: 10.1016/S0302-2838(02)00048-9 |
0.02 |
|
| 2007 |
Retuta D, Ma YY, Kanth R, Boon TH, Sun A, Tanary S. Thermal performance enhancement for CSP packages Proceedings - Electronic Components and Technology Conference. 1690-1695. DOI: 10.1109/ECTC.2007.374022 |
0.02 |
|
| 2009 |
Lund DH, Boon TE, Nathan I. Accountability of experts in the Danish national park process Forest Policy and Economics. 11: 437-445. DOI: 10.1016/j.forpol.2008.08.004 |
0.02 |
|
| 2001 |
Grimbergen MCM, Jonges TGN, Lock MTWT, Van Swol CFP, Boon TA, Van Moorselaar RJA. Photodynamic diagnosis (PDD) of bladder cancer with intravesical 5-aminolevulinic acid induced fluorescence Proceedings of Spie - the International Society For Optical Engineering. 4244: 338-342. DOI: 10.1117/12.427813 |
0.019 |
|
| 2002 |
Van Venrooij GE, Van Melick HH, Eckhardt MD, Boon TA. Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate. The Journal of Urology. 168: 605-9. PMID 12131318 |
0.019 |
|
| 2010 |
Housner JA, Jacobson JA, Morag Y, Pujalte GG, Northway RM, Boon TA. Should ultrasound-guided needle fenestration be considered as a treatment option for recalcitrant patellar tendinopathy? A retrospective study of 47 cases. Clinical Journal of Sport Medicine : Official Journal of the Canadian Academy of Sport Medicine. 20: 488-90. PMID 21079447 DOI: 10.1097/JSM.0b013e3181f3617f |
0.019 |
|
| 2003 |
Kumarasamy Raja M, Boon TTC, Nuntha Kumar K, Jau WS. A fully integrated variable gain 5.75-Ghz LNA with on chip active balun for WLAN Ieee Radio Frequency Integrated Circuits Symposium, Rfic, Digest of Technical Papers. 439-442. |
0.018 |
|
| 2007 |
Kanth KR, Paghasian KY, Retuta D, Toh CH, Tanary S, Boon TH. Better tooling design and effective parameter optimization for successful transfer MUF of flip chips packages Proceedings of the Electronic Packaging Technology Conference, Eptc. 811-817. DOI: 10.1109/EPTC.2007.4469790 |
0.017 |
|
| 2001 |
Boon TA, Van Venrooij GE, Eckhardt MD. Effect of diabetes mellitus on lower urinary tract symptoms and dysfunction in patients with benign prostatic hyperplasia. Current Urology Reports. 2: 297-301. PMID 12084255 |
0.016 |
|
| 2003 |
Boon T, Van den Eynde B. Tumour immunology. Current Opinion in Immunology. 15: 129-30. PMID 12633660 DOI: 10.1016/S0952-7915(03)00010-4 |
0.016 |
|
| 2001 |
Boon T. Expressive puppetry in hospice care. Caring : National Association For Home Care Magazine. 20: 38-40. PMID 11588876 |
0.016 |
|
| 2012 |
Boon TE, Nathan I, Lund DH. The national park process in Denmark: A network governance approach to democratize nature policy-making? Environmental Governance: the Challenge of Legitimacy and Effectiveness. 89-108. DOI: 10.4337/9781849802703.00013 |
0.016 |
|
| 2002 |
Boon T. Examining hospice team meetings. Caring : National Association For Home Care Magazine. 21: 24-6. PMID 12395630 |
0.015 |
|
| 2004 |
van Melick HH, van Venrooij GE, van Swol CF, Boon TA. Cost aspects of transurethral resection of the prostate, contact laser prostatectomy, and electrovaporization. Urology. 63: 882-6. PMID 15134971 DOI: 10.1016/j.urology.2003.12.008 |
0.014 |
|
| 2001 |
Eckhardt MD, van Venrooij GE, van Melick HH, Boon TA. Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well-being. The Journal of Urology. 166: 563-8. PMID 11458069 |
0.014 |
|
| 2005 |
Roos EJ, Van Eijkeren MA, Boon TA, Heintz AP. Pelvic exenteration as treatment of recurrent or advanced gynecologic and urologic cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 15: 624-9. PMID 16014116 DOI: 10.1111/j.1525-1438.2005.00118.x |
0.013 |
|
| 2007 |
Boormans JL, Van Venrooij GEPM, Boon TA. Invasively estimated ICS obstruction classification versus noninvasively assessed bladder outlet obstruction probability in treatment recommendation for luts suggestive of BPH | Invasief bepaalde ICS-classificatie voor obstructie versus niet-invasief verkregen kans op obstructie bij de therapiekeuze voor mannen met LUTS suggestief voor BPH Nederlands Tijdschrift Voor Urologie. 15: 140-144. |
0.013 |
|
| 2001 |
Jennings S, Pinnegar JK, Polunin NVC, Boon TW. Weak cross-species relationships between body size and trophic level belie powerful size-based trophic structuring in fish communities Journal of Animal Ecology. 70: 934-944. DOI: 10.1046/j.0021-8790.2001.00552.x |
0.012 |
|
| 2004 |
Tyrrell CJ, Payne H, Tammela TL, Bakke A, Lodding P, Goedhals L, Van Erps P, Boon T, Van De Beek C, Andersson SO, Morris T, Carroll K. Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. International Journal of Radiation Oncology, Biology, Physics. 60: 476-83. PMID 15380582 DOI: 10.1016/j.ijrobp.2004.03.022 |
0.011 |
|
| 2003 |
van Melick HH, van Venrooij GE, Boon TA. Long-term follow-up after transurethral resection of the prostate, contact laser prostatectomy, and electrovaporization. Urology. 62: 1029-34. PMID 14665349 DOI: 10.1016/S0090-4295(03)00769-6 |
0.011 |
|
| 2011 |
Wai LC, Jaafar NB, Chew M, Sivakumar, Gunasekaran, Kanchet, Witarsa D, Boon TJ, Srinivasa VR, Chai TC, Alastair, Woo J. Fine pitch copper wire bonding on 45nm tech Cu/low-k chip with different bond pad metallurgy 2011 Ieee 13th Electronics Packaging Technology Conference, Eptc 2011. 752-757. DOI: 10.1109/EPTC.2011.6184520 |
0.011 |
|
| 2009 |
Jarvis DSL, Shaofeng C, Boon TT. Investment liberalization in ASEAN: Progress, regress or stumbling bloc? Expansion of Trade and Fdi in Asia: Strategic and Policy Challenges. 138-185. DOI: 10.4324/9780203878996 |
0.01 |
|
| 2004 |
Roos EJ, de Graeff A, van Eijkeren MA, Boon TA, Heintz AP. Quality of life after pelvic exenteration. Gynecologic Oncology. 93: 610-4. PMID 15196852 DOI: 10.1016/j.ygyno.2004.03.008 |
0.01 |
|
| 2015 |
Boon T. Sounding the field: recent works in sound studies. British Journal For the History of Science. 48: 493-502. PMID 26256314 DOI: 10.1017/S0007087415000291 |
0.01 |
|
| 2014 |
Verma PR, Zhang S, Wai CK, Boon TJ, Nair R. Foundry RF technologies Proceedings of Technical Program - 2014 International Symposium On Vlsi Technology, Systems and Application, Vlsi-Tsa 2014. DOI: 10.1109/VLSI-TSA.2014.6839703 |
0.01 |
|
| 2014 |
Aslam MZ, Boon TT. Differential capacitive sensor based interface circuit design for accurate measurement of water content in crude oil 2014 5th International Conference On Intelligent and Advanced Systems: Technological Convergence For Sustainable Future, Icias 2014 - Proceedings. DOI: 10.1109/ICIAS.2014.6869504 |
0.01 |
|
| 2014 |
Hon LY, Boon TH, Lee C. Efficiency and deregulation in the Malaysian electricity sector Energy Studies Review. 21: 40-61. |
0.01 |
|
| 2013 |
Boon T, Coyle C, Sivayoham N. Management of severe sepsis and septic shock in the Emergency Department: a follow-up survey. Emergency Medicine Journal : Emj. 30: 602. PMID 23376879 DOI: 10.1136/emermed-2012-201982 |
0.01 |
|
| 2013 |
Boon T. British science documentaries: Transitions from film to television Journal of British Cinema and Television. 10: 475-497. DOI: 10.3366/jbctv.2013.0151 |
0.01 |
|
| 2013 |
Khairi NA, Jambek AB, Boon TW, Hashim U. Design and analysis of a wireless temperature monitoring system Proceedings - Rsm 2013: 2013 Ieee Regional Symposium On Micro and Nano Electronics. 105-108. DOI: 10.1109/RSM.2013.6706484 |
0.01 |
|
| 2013 |
Mukhtar A, Xia L, Boon TT, Abu Kassim KA. On-road approaching motorcycle detection and tracking techniques: A survey Proceedings - 2013 Ieee International Conference On Control System, Computing and Engineering, Iccsce 2013. 63-68. DOI: 10.1109/ICCSCE.2013.6719933 |
0.01 |
|
| 2012 |
Morag Y, Jamadar DA, Boon TA, Bedi A, Caoili EM, Jacobson JA. Ultrasound of the rotator cable: prevalence and morphology in asymptomatic shoulders. Ajr. American Journal of Roentgenology. 198: W27-30. PMID 22194511 DOI: 10.2214/AJR.10.5796 |
0.01 |
|
| 2012 |
Nathan I, Boon TE. Constraints and Options in Local Forest Management in Cambodia: Is Decentralization a Solution? Journal of Sustainable Forestry. 31: 396-420. DOI: 10.1080/10549811.2011.588479 |
0.01 |
|
| 2011 |
Heng GS, Boon TE. Optimization of IQ mismatch test 2011 Ieee 13th Electronics Packaging Technology Conference, Eptc 2011. 430-434. DOI: 10.1109/EPTC.2011.6184459 |
0.01 |
|
| 2011 |
Boon TL, Agamuthu P. Comparison of methane oxidation potential between compost and black soil at Jeram Landfill Malaysian Journal of Science. 30: 92-98. |
0.01 |
|
| 2011 |
Boon TH, Yee HS, Ting HW. Financial literacy and personal financial planning in Klang Valley, Malaysia International Journal of Economics and Management. 5: 149-168. |
0.01 |
|
| 2011 |
Lund DH, Boon TE, Nathan I. Governance networks and democratic ideals: The case of Thy National Park in Denmark Democracy in Theory and Action. 121-140. |
0.01 |
|
| 2010 |
Woo KT, Chan CM, Mooi CY, -L-Choong H, Tan HK, Foo M, Lee GS, Anantharaman V, Lim CH, Tan CC, Lee EJ, Chiang GS, Tan PH, Boon TH, Fook-Chong S, et al. The changing pattern of primary glomerulonephritis in Singapore and other countries over the past 3 decades. Clinical Nephrology. 74: 372-83. PMID 20979946 |
0.01 |
|
| 2010 |
Chellapandi S, Han CW, Boon TC. The national library of Singapore experience: Harnessing technology to deliver content and broaden access Interlending and Document Supply. 38: 40-48. DOI: 10.1108/02641611011025361 |
0.01 |
|
| 2010 |
Boon T. Historic Passion: Folk work: Growing up in the past History Workshop Journal. 70: 207-216. DOI: 10.1093/hwj/dbq020 |
0.01 |
|
| 2010 |
Boon TE, Broch SW, Meilby H. How financial compensation changes forest owners' willingness to set baside productive forest areas for nature conservation in Denmark Scandinavian Journal of Forest Research. 25: 565-573. DOI: 10.1080/02827581.2010.512875 |
0.01 |
|
| 2010 |
Boon T. On the shopping list Inwood Magazine. 24-25. |
0.01 |
|
| 2010 |
Boon T. More than a plan Inwood Magazine. 18-23. |
0.01 |
|
| 2010 |
Boon T. Lay disease narratives, tuberculosis, and: Health education films Tuberculosis Then and Now: Perspectives On the History of An Infectious Disease. 24-48. |
0.01 |
|
| 2008 |
Jamadar DA, Jacobson JA, Caoili EM, Boon TA, Dong Q, Morag Y, Girish G. Musculoskeletal sonography technique: focused versus comprehensive evaluation. Ajr. American Journal of Roentgenology. 190: 5-9. PMID 18094286 DOI: 10.2214/AJR.07.2433 |
0.01 |
|
| 2007 |
Meijer RP, Boon TA, van Venrooij GE, Wijburg CJ. Long-term follow-up after laser therapy for penile carcinoma. Urology. 69: 759-62. PMID 17445665 DOI: 10.1016/j.urology.2007.01.023 |
0.01 |
|
| 2007 |
Kuwano J, Boon TW. Effects of curing time and stress on the shear strength and deformation characteristics of cement-mixed sand Solid Mechanics and Its Applications. 146: 413-418. |
0.01 |
|
| 2006 |
Harrison PB, Pask D, Maier RRJ, Barton JS, Boon T. Engineering trial of absolute distance interferometry under high acceleration loading Optics Infobase Conference Papers. |
0.01 |
|
| 2004 |
van Dijk L, Kooij DG, Schellevis FG, Kaptein AA, Boon TA, Wooning M. Nocturia: impact on quality of life in a Dutch adult population. Bju International. 93: 1001-4. PMID 15142151 DOI: 10.1111/j.1464-410X.2004.04769.x |
0.01 |
|
| 2004 |
McCulloch S, Burnell G, Boon T, Maier RRJ, Barton JS, Harrison PB, Rigg EJ, Jones JDC. Long-term reliability requirements of fibre optic systems for remote sensing applications Proceedings of Spie - the International Society For Optical Engineering. 5465: 84-91. DOI: 10.1117/12.546010 |
0.01 |
|
| 2004 |
Boon TE, Meilby H, Thorsen BJ. An empirically based typology of private forest owners in Denmark: Improving communication between authorities and owners Scandinavian Journal of Forest Research, Supplement. 19: 45-55. DOI: 10.1080/14004080410034056 |
0.01 |
|
| 2004 |
Francis Poh KS, Boon TH, Sivalingam K, Kuan LB, Sun AYS, Bidin R. Development of high power QFN package Proceedings of the Ieee/Cpmt International Electronics Manufacturing Technology (Iemt) Symposium. 29: 295-300. |
0.01 |
|
| 2003 |
van Melick HH, van Venrooij GE, Boon TA. Laser prostatectomy in patients on anticoagulant therapy or with bleeding disorders. The Journal of Urology. 170: 1851-5. PMID 14532791 DOI: 10.1097/01.ju.0000092502.56901.f7 |
0.01 |
|
| 2003 |
Quah E, Boon TL. The economic cost of particulate air pollution on health in Singapore Journal of Asian Economics. 14: 73-90. DOI: 10.1016/S1049-0078(02)00240-3 |
0.01 |
|
| 2003 |
Van Venrooij GEPM, Van Melick HHE, Boon TA. A comparison of outcomes of TURP in urodynamically obstructed versus urodynamically non-obstructed men | Een vergelijking van de resultaten van TURP bij urodynamisch geobstrueerde mannen en niet-urodynamisch geobstrueerde mannen Nederlands Tijdschrift Voor Urologie. 11: 75-79. |
0.01 |
|
| 2003 |
Bevers RFM, Boon TA, Derogee M. Letter to the editor | Commentaar van de auteurs op ingezonden brief Nederlands Tijdschrift Voor Urologie. 11: 7. |
0.01 |
|
| 2002 |
Eckhardt MD, Van Venrooij GEPM, Boon TA. Careful investigation of diagnostic methods for BPH | De diagnostiek bij BPH onder de loep Nederlands Tijdschrift Voor Urologie. 10: 39-45. |
0.01 |
|
| 2001 |
Boon T. Making the modern world. History Today. 51: 38-44. PMID 17542094 |
0.01 |
|
| 2001 |
Boon T. Long-term planning for authentication solutions. Health Management Technology. 22: 52, 51. PMID 11766435 |
0.01 |
|
| 2001 |
van Melick HH, Gisolf KW, Eckhardt MD, van Venrooij GE, Boon TA. One 24-hour frequency-volume chart in a woman with objective urinary motor urge incontinence is sufficient. Urology. 58: 188-92. PMID 11489695 DOI: 10.1016/S0090-4295(01)01136-0 |
0.01 |
|
| Hide low-probability matches. |
